Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704028 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
NCT00704028: Completed Phase 3 study, sponsored by American Regent.
NCT00704028 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 161 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00704028, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
Interventions
- DRUG Ferric Carboxymaltose
- DRUG Iron Dextran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
What the finished NCT00704028 record still lists
NCT00704028 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose is the first listed.
NCT00704028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00704028 about?
NCT00704028 is a clinical study titled "Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia". The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
What is the current status of trial NCT00704028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2008-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00704028?
The interventions under investigation include: Ferric Carboxymaltose (DRUG), Iron Dextran (DRUG).
Who is sponsoring clinical trial NCT00704028?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00704028's enrollment target sits among peer trials
161 1478th of 2000 higher than 522 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia